Education
About Us
Working with TipRanks
Follow Us
Eyepoint Pharma (EYPT)
:EYPT
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.81Last Year’s EPS
-0.58Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -1.92%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, driven by strong clinical trial enrollment, promising clinical results, and a solid financial position. Despite increased operating expenses and net loss, the company maintains confidence in its strategic focus and potential market opportunities for DURAVYU.Company Guidance
During the EyePoint First Quarter 2025 conference call, the company provided comprehensive guidance on its lead program, DURAVYU, highlighting significant clinical and financial metrics. The company reported that over 90% of patients have been randomized into the LUGANO trial and over 50% into the LUCIA trial, with enrollment completion expected in the second half of 2025. EyePoint's cash reserves stood at $318.2 million, expected to support operations into 2027. Total net revenue for Q1 2025 was $24.5 million, marking an increase from $11.7 million in the same quarter of 2024. Despite a net loss of $45.2 million, EyePoint remains optimistic about DURAVYU's potential, supported by its robust Phase I and Phase II data sets and a favorable safety profile. The company anticipates top-line data from the Phase 3 trials in the latter half of 2026 and is also exploring the drug's potential in diabetic macular edema, with positive Phase 2 results reinforcing its commercial viability in a multibillion-dollar market.Strong Enrollment in Phase 3 Trials
The LUGANO trial has randomized over 90% of patients, while the LUCIA trial has randomized over 50%. Enrollment is significantly ahead of expectations, indicating strong interest and support from both patients and physicians.
Positive Clinical Results for DURAVYU
DURAVYU demonstrated impressive efficacy in the Phase II DAVIO 2 trial, with approximately 2/3 of patients remaining rescue-free for six months and nearly half for one year. The drug also showed a favorable safety profile with no related SAEs.
Financial Position and Guidance
EyePoint ended the first quarter with $318.2 million in cash and investments, affirming guidance that this will support operations into 2027. Total net revenue for the quarter was $24.5 million, a significant increase from $11.7 million the previous year.
Potential Market Opportunities for DURAVYU
DURAVYU is positioned as a differentiated treatment in a multibillion-dollar market for wet AMD and DME, supported by positive Phase 2 results in DME, representing a $3 billion opportunity by 2030.
---
EYPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EYPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $6.25 | $6.09 | -2.56% |
Mar 05, 2025 | $6.08 | $6.58 | +8.22% |
Nov 07, 2024 | $12.08 | $11.59 | -4.06% |
Aug 07, 2024 | $9.02 | $8.65 | -4.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Eyepoint Pharma (EYPT) report earnings?
Eyepoint Pharma (EYPT) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Eyepoint Pharma (EYPT) earnings time?
Eyepoint Pharma (EYPT) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EYPT EPS forecast?
EYPT EPS forecast for the fiscal quarter 2025 (Q2) is -0.81.
---